Disease-modifying therapies for multiple sclerosis have been developed tremendously over the last two decades.
Objective:
The aim of this study was to review the short-, medium-, and long-term safety of alemtuzumab in relapsing remitting multiple sclerosis (RRMS).
Method:
This retrospective observational study (2015–2019) included all patients with highly active or rapidly progressing and aggressive RRMS who were treated with alemtuzumab at the Cabueñes University Hospital. The short-, medium-, and long-term adverse effects were evaluated following the risk management program of the European Medicines Agency.
Results:
39 patients were included, 23 of them received at least two cycles of treatment. Most patients showed at least one adverse event. The following adverse reactions were reported: infusional reactions (17), urinary tract infections (six), thrombopenia (five), and thyroid dysfunction (six).
Conclusion:
In clinical practice alemtuzumab showed an acceptable safety profile in selected patients even if all of them suffered at least one adverse effect. Thorough and prolonged follow-up is required to further confirm the safety of this drug.
Rae-GrantADayGSMarrieRARabinsteinACreeBACGronsethGSHaboubiMHalperJHoseyJPJonesDELisakRPelletierDPotrebicSSitcovCSommersRStachowiakJGetchiusTSDMerillatSAPringsheimT. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the guideline development, dissemination, and implementation subcommittee of the american academy of neurology. Neurology. 2018;90:777.
2.
ReichDSLucchinettiCFCalabresiPA. Multiple sclerosis. N Engl J of Med. 2018;378(2):169–80.
ThompsonAJBanwellBLBarkhofFCarrollWMCoetzeeTComiGCorrealeJFazekasFFilippiMFreedmanMSFujiharaKGalettaSLHartungHPKapposLLublinFDMarrieRAMillerAEMillerDHMontalbanXMowryEMSorensenPSTintoréMTraboulseeALTrojanoMUitdehaagBMJVukusicSWaubantEWeinshenkerBGReingoldSCCohenJA. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162–173.
CohenJAColesAJArnoldDLConfavreuxCFoxEJHartungHPHavrdovaESelmajKWWeinerHLFisherEBrinarVVGiovannoniGStojanovicMErtikBILakeSLMargolinDHPanzaraMACompstonDA. CARE-MS I investigators. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial. Lancet. 2012;380:1819–1828.
13.
ColesAJTwymanCLArnoldDLCohenJAConfavreuxCFoxEJHartungHPHavrdovaESelmajKWWeinerHLMillerTFisherESandbrinkRLakeSLMargolinDHOyuelaPPanzaraMACompstonDA. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial. Lancet. 2012;380:1829–1839.
14.
WillisMDHardingKEPickersgillTPWardleMPearsonORScoldingNJSmeeJRobertsonNP. Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort. Mult Scler. 2016;22(9):1215–1223.
15.
ColesAJCompstonDASelmajKWLakeSLMoranSMargolinDHNorrisKTandonPK. CAMMS223 Trial Investigators. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.. N Engl J Med. 2008;359:1786–1801.
16.
RauDLangMHarthANaumannMWeberFTumaniHBayasA. Listeria meningitis complicating alemtuzumab treatment in multiple sclerosis–report of two cases. Int J Mol Sci. 2015;16:14669–76.
17.
ZiemssenTThomasK. Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: An update on the clinical trial evidence and data from the real world. Ther Adv in Neurol Disord. 2017;10(10):343–359.
18.
HavrdovaEArnoldDLCohenJAHartungHPFoxEJGiovannoniGSchipplingSSelmajKWTraboulseeACompstonDASMargolinDHThangaveluKRodriguezCEJodyDHoganRJXenopoulosPPanzaraMAColesAJ. Alemtuzumab CARE-MS I 5-year follow-up. Neurology. 2017;89:1107–1116.
19.
ColesAJCohenJAFoxEJGiovannoniGHartungHPHavrdovaESchipplingSSelmajKWTraboulseeACompstonDASMargolinDHThangaveluKChirieacMCJodyDXenopoulosPHoganRJPanzaraMAArnoldDL. Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings. Neurology. 2017;89(11):1117–1126.
20.
ButzkuevenHKapposLPellegriniFTrojanoMWiendlHPatelRNZhangAHotermansCBelachewS. Efficacy and safety of natalizumab in multiple sclerosis: Interim observational programme results. J Neurol Neurosurg Psychiatry. 2014;85:1190–1197.
21.
O’ConnorPGoodmanAKapposLLublinFPolmanCRudickRAHauswirthKCristianoLMForrestalFDudaP. Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study. Neurology. 2014;83:78–86.
22.
BloomgrenGRichmanSHotermansCSubramanyamMGoelzSNatarajanALeeSPlavinaTScanlonJVSandrockABozicC. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366:1870–1880.
